How did ONCY's Q4 2024 expenses impact its net profit?

Oncolytics Biotech Inc.'s (ONCY) Q4 2024 expenses had a significant impact on its net profit, with the company reporting a net loss of $5.57 million for the quarter. The following highlights the key factors that contributed to this result: 1. **Increased Net Loss**: Compared to the previous year's net loss of $3.9 million in Q4 2023, ONCY experienced a substantial increase in net loss, reaching $8 million for Q4 2024. This rise was primarily due to higher operating expenses and general and administrative costs. 2. **General and Administrative Expenses**: The company's General and Administrative (G&A) expenses amounted to $3.9 million for Q4 2024, representing a slight decrease from the $4.2 million recorded in the same quarter of the previous year. Despite this minor reduction, G&A expenses continued to strain the company's financials. 3. **Research and Development Costs**: Oncolytics Biotech Inc. maintained its Research and Development (R&D) expenses at $4.6 million for Q4 2024, similar to the $4.7 million spent in the corresponding quarter of 2023. R&D costs are critical for the company's ongoing clinical trials and product development, contributing to the pressure on net profit. 4. **Cash Flow Challenges**: The company's cash and cash equivalents decreased to $15.9 million as of December 31, 2024, which could indicate cash flow challenges resulting from operational expenses and the need for funding to support ongoing research and development activities. In summary, ONCY's Q4 2024 expenses, particularly increased net loss, general and administrative costs, and research and development expenditures, had a profound impact on the company's net profit, leading to a significant financial strain.